https://www.selleckchem.com/products/odm208.html
d on KS) incurred significantly greater all-cause and VTE-related healthcare costs compared with cancer patients at lower risk of VTE.IntroductionSafety and tolerability is a critical area where improvements are needed to decrease the attrition rates during development of new drug candidates. Modeling approaches, when smartly implemented, can contribute to this aim.Areas coveredThe focus of this review was on modeling approaches applied to four kinds of drug-induced toxicities hematological, immunological, cardiovascular (CV) and liver t
Like
Comment
Share
